GRFS · NASDAQ · Drug Manufacturers - General

Grifols (ADR)

Builds plasma-derived therapies, diagnostics, and biologic supplies around an integrated plasma network.

$7.69
After-hours close0.00 (0.00%)
At close$7.69(−1.66%)

Breakdown13F · Form 4

Institutions 16.88%Insiders

Shares outstanding 845.97M · Float 834.63M · 98.7% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
Brandes Investment Partners, LP37.82M4.47%13FAug 14, 2026
Capital World Investors22.91M2.71%13FAug 12, 2026
Permian Investment Partners, LP19.74M2.33%13FAug 14, 2026
Black Creek Investment Management Inc.7.68M0.91%13FAug 12, 2026
Bank of America Corp /DE/6.55M0.77%13FAug 14, 2026

Institutions13F, as of Jun 30, 2026

172 holders · 142.80M shares · 19 new positions · 70 increased · 69 reduced · 38 closed

HolderShares% outstandingChg q/qFiled
Brandes Investment Partners, LP37.82M4.47%+1.48MAug 14, 2026
Capital World Investors22.91M2.71%−13.3KAug 12, 2026
Permian Investment Partners, LP19.74M2.33%+386.0KAug 14, 2026
Black Creek Investment Management Inc.7.68M0.91%−704.4KAug 12, 2026
Bank of America Corp /DE/6.55M0.77%+2.22MAug 14, 2026
Millennium Management LLC4.37M0.52%−635.6KAug 14, 2026
Flat Footed LLC4.35M0.51%+2.98MAug 14, 2026
Jupiter Topco LLC2.96M0.35%+2.96MnewAug 14, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Brandes Investment Partners, LP24.30%27.22M13GMay 14, 2026
Permian Investment Partners, LP7.10%18.61M13GFeb 17, 2026

InsidersForm 4

Latest trades

Nothing filed in the last 12 months.

CongressHouse and Senate disclosures

Not reported.